Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead
- 1 March 2018
- journal article
- review article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 148, 436-452
Abstract
No abstract availableKeywords
Funding Information
- Department of BiotechnologyDepartment of Biotechnology (DBT) (BT/PR9624/MED/30/1253/2013)
This publication has 129 references indexed in Scilit:
- Piperidine Acetic Acid Based γ-Secretase Modulators Directly Bind to Presenilin-1ACS Chemical Neuroscience, 2011
- Phenylpiperidine‐type γ‐secretase modulators target the transmembrane domain 1 of presenilin 1The EMBO Journal, 2011
- Not(ch) just development: Notch signalling in the adult brainNature Reviews Neuroscience, 2011
- ADAM10 is the physiologically relevant, constitutive α‐secretase of the amyloid precursor protein in primary neuronsThe EMBO Journal, 2010
- Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike PropertiesACS Chemical Neuroscience, 2010
- Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled TrialJAMA, 2009
- Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer DiseaseArchives of Neurology, 2008
- Substrate-targeting γ-secretase modulatorsNature, 2008
- Notch signalling in vertebrate neural developmentNature Reviews Neuroscience, 2006
- Presenilin 1 is required for Notch 1 and Dll1 expression in the paraxial mesodermNature, 1997